Martin H. Huber's Insider Trades & SAST Disclosures
Martin H. Huber's most recent trade in Syndax Pharmaceuticals Inc was a trade of 25,000 Common Stock done . Disclosure was reported to the exchange on Feb. 5, 2025.
Add Superstar Alert
Note
This is a custom search result for pattern Martin H. Huber.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Syndax Pharmaceuticals Inc
|
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 25,000 | 74,000 (0%) | 0% | 0 | Common Stock | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 816,300 | 816,300 | - | - | Stock Option (Right to Buy) | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 181,400 | 181,400 | - | - | Restricted Stock Unit | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 11,062 | 127,389 (0%) | 0% | 0 | Common Stock | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 11,062 | 33,188 | - | - | Restricted Stock Unit | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 0.58 per share. | 15 Jan 2025 | 4,514 | 122,875 (0%) | 0% | 0.6 | 2,618 | Common Stock |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 166,750 | 166,750 (0%) | 0% | 0 | Common Stock | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 166,750 | 500,250 | - | - | Restricted Stock Unit | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 1.76 per share. | 11 Sep 2024 | 50,423 | 116,327 (0%) | 0% | 1.8 | 88,744 | Common Stock |
|
Syndax Pharmaceuticals Inc
|
Huber H. Martin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 17,000 | 49,000 (0%) | 0% | 0 | Common Stock | |
|
Mersana Therapeutics Inc
5-year low |
H. Huber Martin | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 199,125 | 199,125 | - | - | Stock Option (Right to Buy) | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 44,250 | 44,250 | - | - | Restricted Stock Unit | |
|
Xilio Therapeutics Inc
|
Martin H. Huber | PRESIDENT AND HEAD OF R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2023 | 136,500 | 136,500 | - | - | Stock Option (right to buy) | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 4,477 | 4,477 | - | - | Stock Option (right to buy) | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 18,355 | 18,355 | - | - | Stock Option (right to buy) | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 14,467 | 14,467 (0%) | 0% | 0 | Common Stock | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 3,375 | 3,375 | - | - | Stock Option (right to buy) | |
|
Syndax Pharmaceuticals Inc
|
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 16,000 | 32,000 (0%) | 0% | 0 | Common Stock | |
|
Xilio Therapeutics Inc
|
Martin H. Huber | PRESIDENT AND HEAD OF R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 136,500 | 136,500 | - | - | Stock Option (right to buy) | |
|
Xilio Therapeutics Inc
|
Martin H. Huber | PRESIDENT AND HEAD OF R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
|
Xilio Therapeutics Inc
|
Martin H. Huber | PRESIDENT OF R&D AND CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
|
Syndax Pharmaceuticals Inc
|
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 16,000 | 16,000 (0%) | 0% | 0 | Common Stock | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,185 | 10,185 | - | - | Stock Option (right to buy) | |
|
Xilio Therapeutics Inc
|
Martin H. Huber | President of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2021 | 157,058 | 157,058 | - | - | Stock Option (right to buy) | |
|
Syndax Pharmaceuticals Inc
|
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2021 | 35,000 | 35,000 | - | - | Stock Options (Right to buy) | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2021 | 25,050 | 25,050 | - | - | Stock Option (right to buy) | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 2,490 | 2,490 | - | - | Stock Option (right to buy) | |
|
Mersana Therapeutics Inc
5-year low |
Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Apr 2020 | 48,096 | 48,096 | - | - | Stock Option (right to buy |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges